SkinPen Precision now under direct management in the UK
SkinPen Precision, the first microneedling device cleared by the FDA, now has a direct presence in the UK and Ireland.
SkinPen's operations in the UK were previously managed by BioActive Aesthetics. Now, Crown Aesthetics, formerly known as Bellus Medical, will look after SkinPen's presence directly, with a dedicated UK website and support team.
The company said the market arrival of Crown Aesthetics was "a significant organisational investment that confirms Crown’s commitment to its customers and patients... Crown’s investment ensures a best-in-class level of service that SkinPen Precision customers and patients have come to expect across the globe."
“By directly supporting our SkinPen customers, we will help them grow their practices by driving patient demand,” said Andy Moulton, vice president of international sales for Crown Aesthetics. "They will now receive the superior level of training, education, and customer service they deserve.”
Launched in 2013, SkinPen Precision is a Class IIa medical device. US-engineered and manufactured, the skin remodeling device is indicated for treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appearance of fine lines and wrinkles on the face and neck.
SkinPen also treats pigmentation conditions including melasma, vitiligo and sun/age spots. SkinPen Precision works by creating controlled micro-injuries to stimulate the body’s natural wound-healing response and remodel scar tissue. It is clinically proven to be effective on all Fitzpatrick skin types. Patients experience minimal cellular damage and little to no downtime.